ELI LILLY AND COMPAN

LLY
Delayed Quote. Delayed  - 06/18 04:10:00 pm
218.55USD -1.65%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Pharmaceuticals
  Pharmaceuticals
   Other Pharmaceuticals
Eli Lilly and Company is a drug manufacturing company. The Company discover, develop, manufacture, and market products in a human pharmaceutical product segment. The Company’s products include Diabetes and other endocrinology products, including Baqsimi, Basaglar, Forteo, Humalog, Humatrope, Humulin, Jardiance, Trajenta and Trulicity. Its Immunology products include Olumiant and Taltz. Its Neuroscience products include Cymbalta, Emgality, Reyvow, Strattera and Zyprexa. Its Oncology products include Alimta, Cyramza, Erbitux and Verzenio. Other product includes Cialis, for the tratment of erectile dysfunction and benign prostatic hyperplasia. The Company manufacture and distribute its products through facilities in the United States, Puerto Rico, and 8 other countries. Its products are sold in approximately 120 countries.

Number of employees : 35 000 people.
Sales per Business
20192020
USD
(in Million)
%USD
(in Million)
%
Pharmaceutical Products 22,320100% 24,540100%
Sales per region
2020
USD
(in Million)
%
United States 14,22958%
Europe 4,18817.1%
Japan 2,58310.5%
Other Foreign Countries 2,4239.9%
China 1,1174.6%
Managers
Name Title
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Melissa Stapleton Barnes Senior VP, Chief Ethics & Compliance Officer
Jon Erik Fyrwald Independent Director
Michael L. Eskew Independent Director
Ralph Alvarez Independent Director
Katherine Baicker Independent Director
Shareholders
Name Equities %
Lilly Endowment, Inc. 109,412,100 11.4%
Capital Research & Management Co. 109,033,091 11.4%
The Vanguard Group, Inc. 65,660,721 6.85%
The PNC Financial Services Group, Inc. 52,012,151 5.42%
PNC Bank, NA (Investment Management) 51,595,739 5.38%
PRIMECAP Management Co. 35,378,235 3.69%
SSgA Funds Management, Inc. 32,506,101 3.39%
Wellington Management Co. LLP 31,788,979 3.31%
Fidelity Management & Research Co. LLC 28,521,589 2.97%
T. Rowe Price Associates, Inc. (Investment Management) 26,155,001 2.73%
Company contact information
Lilly Corporate Center
IN 46285 Indianapolis, Indiana


Phone : +1 617-225-3226
Fax :
web site : https://investor.lilly.com/
Markets and indexes
-
- International Market
- S&P 100 / S&P 500, Stoxx Americas 100, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  LILY11B:BZ
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
ELI LILLY AND COMPANY27.89%198 668
JOHNSON & JOHNSON2.92%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.5.43%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.5.57%199 795
ELI LILLY AND COMPANY29.44%198 668
MERCK & CO., INC.-6.34%193 981
NOVO NORDISK A/S20.59%188 360
ASTRAZENECA PLC14.47%151 865
BRISTOL-MYERS SQUIBB COMPANY7.16%148 417
AMGEN INC.3.81%137 135
SANOFI11.79%130 457
GLAXOSMITHKLINE PLC6.07%98 277
JIANGSU HENGRUI MEDICINE CO., LTD.-23.09%70 523
ALLERGAN PLC0.97%63 659
CHUGAI PHARMACEUTICAL CO., LTD.-22.77%63 368
BAYER AG9.54%61 438
TAKEDA PHARMACEUTICAL COMPANY LIMITED-0.85%52 846
DAIICHI SANKYO COMPANY, LIMITED-28.98%43 629
ASTELLAS PHARMA INC.21.89%32 733
Brand Portfolio
ARMO BIOSCIENCES
ARMO BIOSCIENCES
CHEMGEN
CHEMGEN
ELI LILLY AND COMPANY
ELI LILLY AND COMPANY
IMCLONE SYSTEMS
IMCLONE SYSTEMS
LOXO ONCOLOGY
LOXO ONCOLOGY
PHARMASERVE-LILLY
PHARMASERVE-LILLY
» More brands of Eli Lilly And Company